This review summarizes important studies regarding Helicobacter pylori therapy published from March 2021 to March 2022. Some of the major themes that emerge involve studies assessing the efficacy of high dose dual therapy regimens, the huge promise shown by vonoprazan as a component of eradication therapy and the use of personalised therapy. The nature of much of the work conducted over the last year has been dictated somewhat by the demands of the pandemic era, with far more systematic reviews and data syntheses and fewer original data on important factors such as resistance rates. Nonetheless, other studies have also been published which strengthen the importance of bismuth-based therapies, quadruple regimens and the use of novel tetracyclines and fluoroquinolones. A further body of work was undertaken on factors influencing the success and failure of therapies, all of which greatly enabling us to tackle the twin problems of antibiotic resistance and patient adherence to therapy.